Lilly, Boehringer enter R&D pact to test breast cancer combo

The companies have a proven track record with Jardiance, but can they extrapolate their success in metabolics to oncology?

By Nicole Gray • July 14, 2016

Sage soars after small study of postpartum depression drug shows benefit

Seven out of 10 women in the mid-stage trial experienced remission from depression after receiving Sage's drug. 

By Ned Pagliarulo • July 12, 2016

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

Cancer drug could benefit Parkinson's patients, study shows

Researchers at Georgetown University believe a leukemia drug helped boost dopamine production in 11 patients and have plans for further study. 

By Ned Pagliarulo • July 11, 2016

Hours after Juno tragedy, Kite announces full-enrollment in CAR-T trial

The company's ZUMA-1 trial involves a similar pre-conditioning regimen as was present in Juno's ROCKET trial, which led to three patient deaths last week. 

By Edwin Lopez • July 11, 2016

Pfizer, German Merck to test new combo against ovarian cancer

The two companies are aggressively developing the checkpoint inhibitor avelumab in hopes of catching early leaders in immuno-oncology. 

By Nicole Gray • July 7, 2016

AbbVie bet on Ablynx gets boost after arthritis drug shows promise

Belgium-based Ablynx said its experimental drug matched Roche's Actemra in improving symptoms of rheumatoid arthritis. 

By Ned Pagliarulo • July 7, 2016

Pfizer's PCSK9 drug notches two Phase 3 wins

Bococizumab would be the third PCSK9 drug to hit U.S. markets, but Pfizer hopes to distinguish it with stronger clinical data. 

By Nicole Gray • June 30, 2016

Shire's adult ADHD drug shows promise in late-stage study

But another drug for a rare eye condition failed to meet its primary goal in a mid-stage study, somewhat offsetting the positive news for Shires' ADHD drug.

By Nicole Gray • June 30, 2016

Cancer Moonshot summit adds new partnerships to lofty goals

At the summit, FDA commissioner Robert Califf said the agency would consolidate clinical review of cancer products into a new Oncology Center of Excellence. 

By Nicole Gray • June 30, 2016

Tesaro soars after ovarian cancer drug meets Phase 3 goal

Results showed Tesaro's drug, niraparib, extended progression-free survival times by 16 months for certain patients, compared to a placebo. 

By Ned Pagliarulo • June 29, 2016

GW Pharma shares jump on Phase 3 data for cannabis-based drug

Based in London, the company has been developing Epidiolex for treatment of a number of rare childhood seizure disorders.

By Ned Pagliarulo • June 27, 2016

Study says Novartis heart med could prevent 28,000 US deaths per year

Despite a positive clinical profile, sales of Entresto have struggled to get off the ground since the drug launched last year. 

By Nicole Gray • June 24, 2016

Eleven Bio slashes workforce after drug test failures

Only six employees remain after the company cut 70% of its staff. 

By Nicole Gray • June 23, 2016

Epizyme partners with Roche to test cancer drug combo

The companies will test Epizyme's drug in combination with Roche's newly-approved Tecentriq, a hot commodity for oncology partnerships. 

By Ned Pagliarulo • June 23, 2016

First human study of CRISPR approved by federal panel

Researchers from the University of Pennsylvania plan to use the gene-editing technology to enhance immune cells against three types of cancer.

By Ned Pagliarulo • June 22, 2016

Takeda begins field testing norovirus vaccine

There is no vaccine available for the highly-infectious virus, and Takeda's drug is the only candidate currently in clinical trials, according to the company. 

By Ned Pagliarulo • June 21, 2016

Incidence of Parkinson's may be increasing: Mayo Clinic study

In a Minnesota study spanning three decades, the disease and related symptoms appeared to become more common in men. 

By Nicole Gray • June 21, 2016

Epizyme stock falls after mixed Phase 2 results for blood cancer drug

Early data showed treatment with tazemetostat helped shrink tumors in some patients with non-Hodgkin lymphoma, but the response rate was lower than some had expected. 

By Nicole Gray • June 20, 2016

NIH panel to review proposal for first in human test of CRISPR

Researchers at the University of Pennsylvania plan to use the gene-editing technology to modify two genes in T-cells. 

By Ned Pagliarulo • June 17, 2016

Merck's Keytruda beats out chemotherapy in lung cancer study

The positive Phase 3 results likely position the immunotherapy for first-line treatment of non-small cell lung cancer.

By Ned Pagliarulo • June 16, 2016

NYC-based Rgenix raises $33 million to advance cancer immunotherapy

The biotech hopes to start Phase 1 testing on the drug this fall. 

By Nicole Gray • June 15, 2016

Lilly and Boehringer's Jardiance sets new bar, shows kidney benefit

Other drugmakers have rushed to match the drug's previously proven cardiovascular benefit, but new data shows it can help slow the progression of kidney disease. 

By Nicole Gray • June 15, 2016

Teva hands back global rights for heart drug to Australian Mesoblast

Mesoblast will now have to fund Phase 3 development of the drug without a major partner. 

By Nicole Gray • June 15, 2016

Infinity Pharma to lay off one-fifth of staff in wake of phase 2 setback

Markets reacted sharply, with Infinity stock dropping in value by nearly 72% Tuesday. 

By Nicole Gray • June 14, 2016

Merck eyes US approval with positive data on Lantus copy

Similar to Eli Lilly's recently approved Basaglar, Merck is developing MK-1293 as a "follow-on biologic" to Sanofi's insulin glargine. 

By Nicole Gray • June 14, 2016